Canaccord Genuity Group Cuts Stryker (NYSE:SYK) Price Target to $400.00
by Jessica Moore · The Cerbat GemStryker (NYSE:SYK – Get Free Report) had its price objective lowered by Canaccord Genuity Group from $435.00 to $400.00 in a report issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the medical technology company’s stock. Canaccord Genuity Group’s target price would indicate a potential upside of 35.39% from the stock’s previous close.
A number of other equities research analysts have also recently commented on SYK. UBS Group decreased their price target on shares of Stryker from $400.00 to $380.00 and set a “neutral” rating for the company in a research note on Tuesday, March 17th. Needham & Company LLC lowered their target price on shares of Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a report on Friday. Piper Sandler restated an “overweight” rating on shares of Stryker in a report on Tuesday, January 27th. BTIG Research lowered their target price on shares of Stryker from $397.00 to $379.00 and set a “buy” rating on the stock in a report on Friday. Finally, Sanford C. Bernstein set a $410.00 target price on shares of Stryker in a report on Friday. Seventeen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, Stryker currently has an average rating of “Moderate Buy” and a consensus price target of $403.73.
View Our Latest Stock Report on Stryker
Stryker Trading Down 6.3%
Shares of NYSE:SYK traded down $19.70 during trading on Friday, reaching $295.43. The stock had a trading volume of 4,518,113 shares, compared to its average volume of 2,089,251. The firm’s fifty day moving average is $345.67 and its 200 day moving average is $356.95. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.21 and a current ratio of 1.89. Stryker has a 52 week low of $294.55 and a 52 week high of $404.87. The stock has a market cap of $113.15 billion, a price-to-earnings ratio of 35.17, a P/E/G ratio of 1.84 and a beta of 0.92.
Stryker (NYSE:SYK – Get Free Report) last issued its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a return on equity of 24.41% and a net margin of 12.92%.The business had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $6.34 billion. During the same quarter in the previous year, the firm posted $2.84 earnings per share. The company’s revenue for the quarter was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, equities analysts forecast that Stryker will post 14.91 EPS for the current fiscal year.
Insiders Place Their Bets
In other Stryker news, Director Ronda E. Stryker sold 250,000 shares of the business’s stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total value of $90,730,000.00. Following the transaction, the director directly owned 2,457,331 shares in the company, valued at $891,814,566.52. The trade was a 9.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 4.60% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Stryker
Large investors have recently added to or reduced their stakes in the company. Simplicity Wealth LLC raised its position in shares of Stryker by 10.9% in the first quarter. Simplicity Wealth LLC now owns 827 shares of the medical technology company’s stock valued at $272,000 after purchasing an additional 81 shares during the period. Candriam S.C.A. lifted its position in shares of Stryker by 1.6% during the first quarter. Candriam S.C.A. now owns 167,146 shares of the medical technology company’s stock worth $54,923,000 after acquiring an additional 2,694 shares in the last quarter. Osprey Private Wealth LLC lifted its position in shares of Stryker by 1,398.7% during the first quarter. Osprey Private Wealth LLC now owns 10,491 shares of the medical technology company’s stock worth $3,447,000 after acquiring an additional 9,791 shares in the last quarter. Sequoia Financial Advisors LLC lifted its position in shares of Stryker by 3.6% during the first quarter. Sequoia Financial Advisors LLC now owns 14,503 shares of the medical technology company’s stock worth $4,766,000 after acquiring an additional 506 shares in the last quarter. Finally, AlpenGlobal Capital LLC purchased a new stake in shares of Stryker during the first quarter worth $1,953,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.
Key Stories Impacting Stryker
Here are the key news stories impacting Stryker this week:
- Positive Sentiment: Stryker maintained its FY‑2026 outlook — $14.90–$15.10 adjusted EPS and 8%–9.5% organic sales growth — signaling management’s confidence in recovery from the cyber incident. Article Title
- Positive Sentiment: Operational cash flow and net income showed notable improvement year-over-year (operating cash flow jumped and net income rose), which supports longer‑term cash generation and capital investment. Article Title
- Neutral Sentiment: Stryker will present at the Bank of America Global Healthcare Conference on May 13 — an opportunity for management to address the cyber recovery and investor questions, but not an immediate catalyst for results. Article Title
- Negative Sentiment: Q1 results missed consensus: adjusted EPS of $2.60 vs. ~ $2.98 expected and revenue of $6.02B vs. ~$6.34B. Management cited a cyber incident that disrupted production, pressured margins and slowed growth — the primary driver of today’s selling pressure. Article Title
- Negative Sentiment: Several Wall Street firms cut Stryker price targets this morning (JPMorgan to $400, Wells Fargo to $418, Needham/BTIG lowered targets) — ratings largely remain buy/overweight but lower targets reduce near‑term upside expectations and add selling pressure. Article Title
Stryker Company Profile
Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.